Published by Ministry of Health, Labour and Welfare



Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

## Revision of Precautions Levodopa, Levodopa/Carbidopa hydrate, Levodopa/Carbidopa hydrate/Entacapone, Levodopa/Benserazide hydrochloride

April 21, 2016

## Non-proprietary name

- a. Levodopa
- b. Levodopa/Carbidopa hydrate
- c. Levodopa/Carbidopa hydrate/Entacapone
- d. Levodopa/Benserazide hydrochloride

## Safety measure

Precautions should be revised in the package insert.

In the Clinically significant adverse reaction subsection of the Adverse reaction section, the following text should be added (underlined parts are revised):

## Angle closure glaucoma

Angle closure glaucoma associated with sudden increased intraocular pressure may occur. If any abnormalities, such as blurred vision, eye pain, hyperemia, headache, and nausea, are observed, administration of this drug should be discontinued, and appropriate measures should be adopted immediately.

Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>